Literature DB >> 31535668

Genetic heterogeneity of indeterminate thyroid nodules assessed preoperatively with next-generation sequencing reflects the diversity of the final histopathologic diagnosis.

Martyna Borowczyk1, Ewelina Szczepanek-Parulska2, Szymon Dębicki2, Bartłomiej Budny2, Frederik A Verburg3, Dorota Filipowicz2, Elżbieta Wrotkowska2, Małgorzata Janicka-Jedyńska4, Barbara Więckowska5, Lidia Gil6, Katarzyna Ziemnicka2, Marek Ruchała2.   

Abstract

INTRODUCTION: Inconclusive cytologic results of thyroid fine‑needle aspiration biopsy (FNAB) include atypia or follicular lesion of undetermined significance (FLUS) and follicular neoplasm or suspicious for follicular neoplasm (SFN).
OBJECTIVES: We aimed to assess the genetic background of indeterminate thyroid nodules and to identify new genetic pathways potentially involved in the development of follicular thyroid cancer. PATIENTS AND METHODS: Genomic DNA was isolated from FNAB samples from 25 white patients (2 men; 23 women) diagnosed preoperatively with FLUS (n = 16) and SFN (n = 9). Next‑generation sequencing (NGS) was performed. The results were compared with clinical data, including final postsurgical diagnoses.
RESULTS: The malignancy rate was 28%. KDR, RET, and TP53 gene mutations were most frequent in FLUS and SFN samples finally diagnosed as cancers, whereas alterations in RET, TP53, FLT3, APC, and PDGFRA predominated in benign tumors. KDR tended to be more common in malignant samples (75% vs 20%, P = 0.1). A total number of mutated genes was higher in patients with benign tumors (17 vs 11, P = 0.02), but there was no difference between groups in the mean number of mutations per patient (4.9 [range, 1-9]).
CONCLUSIONS: We showed that the heterogeneity in the genetic background of indeterminate thyroid nodules corresponds to their histopathologic diversity. The role of KDR as a possible malignancy marker needs to be confirmed. Glass slides with FNAB samples may constitute a reliable source of genetic material for NGS studies, providing a better insight into the molecular profile of thyroid nodules.

Entities:  

Year:  2019        PMID: 31535668     DOI: 10.20452/pamw.14979

Source DB:  PubMed          Journal:  Pol Arch Intern Med        ISSN: 0032-3772


  2 in total

1.  Are molecular tests necessary to diagnose NIFTP?

Authors:  Artur Kuchareczko; Janusz Kopczyński; Artur Kowalik; Kinga Hińcza; Agnieszka Płusa; Stanisław Góźdź; Aldona Kowalska
Journal:  Genes Cancer       Date:  2021-03-15

2.  Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.

Authors:  Busra Yaprak Bayrak; Ahmet Tugrul Eruyar
Journal:  BMC Endocr Disord       Date:  2020-04-15       Impact factor: 2.763

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.